Lakefront Biotherapeutics (GLPGF) Cash & Equivalents Growth (3y) (2016 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Cash & Equivalents Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | -25.80% |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | -17.71% |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | -15.41% |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 8.23% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 47.78% |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | -23.18% |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 37.45% |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -21.12% |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -16.27% |
| Dec 31, 2025 | -41.78% |
| Mar 31, 2025 | -56.78% |
| Dec 31, 2024 | -70.05% |
| Dec 31, 2023 | -58.69% |
| Mar 31, 2023 | -64.70% |
| Dec 31, 2022 | -36.87% |
| Mar 31, 2022 | 0.42% |
| Dec 31, 2021 | 20.14% |
| Jun 30, 2021 | 35.72% |
| Dec 31, 2020 | 23.38% |
| Jun 30, 2020 | 23.69% |
| Mar 31, 2020 | 43.93% |
| Dec 31, 2019 | 25.17% |
| Jun 30, 2019 | 5.93% |
| Mar 31, 2019 | 8.46% |
| Dec 31, 2018 | 58.07% |
| Dec 31, 2017 | 79.44% |
| Mar 31, 2017 | 394.91% |
| Dec 31, 2016 | 77.45% |